SAN DIEGO, CA – (Marketwired) – 10/03/13 – NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce the domestic launch of the XLIF Decade™ Plate.
The XLIF Decade Plate is the Company’s latest advancement in providing surgeon customers with an option for a single-approach XLIF® and fixation.
The prevailing strategy in designing the XLIF Decade Plate was to incorporate the Company’s ten years of XLIF experience into a fixation system built upon the latest technologies while offering uncompromised biomechanical characteristics. The plate will be exhibited at the upcoming North American Spine Society (NASS) conference in October.
“In combination with the CoRoent® XL-XW 26mm wide interbody implant, the XLIF Decade Plate was designed to provide enhanced stabilization following XLIF surgery,” said William Smith, M.D. “In many patients, the new plate design may enable me to eliminate the need for posterior surgery, and may offer a comparable biomechanical construct. This option could significantly reduce the O.R. time required for surgery for some patients and may allow my patients the benefit of a more rapid return to their normal activities.”
The plate is a simple, yet comprehensive stabilization solution which was designed with four points of fixation for enhanced rigidity and load sharing properties. Through a reduction in operative steps and improved plate geometry, the product was designed to help facilitate a faster XLIF surgical technique.
“The XLIF Decade Plate delivers on our mission to improve patient outcomes with innovation,” said Alex Lukianov, NuVasive Chairman and Chief Executive Officer. “NuVasive is the market share leader within the lateral fusion market, and our drive to consistently improve our procedurally integrated approach will enable us to maintain that foothold.”
The plate is contoured specifically for the MaXcess IV retractor and CoRoent XL family of implants, which results in a seamless technique. Additionally, the product represents the pinnacle in single-approach lateral spinal stabilization and fusion with minimized exposure.
About the XLIF Decade™ Plate:
The XLIF Decade Plate is the latest advancement in intraoperative flexibility for a single-approach lateral fusion and fixation that conforms to a standard XLIF surgical technique.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company’s principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
NuVasive’s solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive’s press releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Juliet C. Cunningham